SUNNYVALE, California,
April 28, 2016 /PRNewswire/ --
Next generation delivery system designed for increased
throughput, higher reliability and ease of
serviceability
Accuray Incorporated (NASDAQ: ARAY) announced the company will
showcase its portfolio of radiation therapy delivery systems and
software solutions at the annual European Society for Therapeutic
Radiology and Oncology (ESTRO) meeting being held in Turin, Italy April 29 -
May 3, 2016. Meeting attendees are invited to attend the
unveiling of the company's newest innovation, the Radixact™
Treatment Delivery System*, at Accuray booth #1300 on Saturday, April 30 at 10:10 a.m.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://photos.prnewswire.com/prnh/20160427/360580 )
The Radixact System is the next generation TomoTherapy®
platform. The Radixact System, in combination with the Precision™
Treatment Planning System* and iDMS™ Data Management System*, is
intended to provide clinicians with a foundation for expanded
clinical capabilities to help ensure the platform will be highly
utilized for years to come, while driving excellence in outcomes
across a wide range of patient cases.
The Radixact technology is being designed to enable faster image
acquisition and treatment delivery.
The high output, compact linear accelerator is capable of
producing a dose rate of 1,000 MU per minute, and imaging speed
will increase.
"The addition of the Radixact technology to the Accuray
CyberKnife® System and TomoTherapy® System product portfolio
reinforces the company's commitment to bringing to market
innovative radiation therapy solutions that make a difference in
the lives of people with cancer," said Lionel Hadjadjeba who serves
as corporate senior vice president, and president worldwide
commercial operations at Accuray. "For more than two decades, the
company has introduced technology which has helped drive the
evolution of radiotherapy treatments. We are dedicated to providing
our customers with more powerful, more flexible options that make
precise radiation treatment available to more patients."
Additional meeting highlights and events:
- Precision Treatment Planning System and iDMS Data Management
System
The Radixact System is being designed to integrate with the
company's next generation treatment planning and data management
systems to take full advantage of the platform's delivery
capabilities, with the intention of significantly improve the user
experience through intuitive and simplified workflows.
- InCise™ Multileaf Collimator (MLC)
The InCise MLC is the world's first MLC to be available on a
robotic platform, the CyberKnife M6™ System. The combination of
delivery system and MLC is demonstrating to be an extremely
efficient delivery system, significantly reducing treatment times
while maintaining high standards of conformality and dose
distribution for a broad range of clinical cases. Accelerated
treatment time means greater throughput for the hospital and less
time on the treatment couch for patients.
- Work in progress: treatment planning for TomoTherapy® System
and CyberKnife® System in RayStation®
Accuray and RaySearch have expanded their existing relationship
which will lead to the integration of treatment planning support
for the TomoTherapy® and CyberKnife® Systems in the RayStation®
treatment planning system. For the first time, clinics will have
access to an advanced, integrated treatment planning system for
Accuray treatment delivery systems and conventional linear
accelerators, getting unprecedented choice of radiation therapy
planning and treatment delivery systems to best meet patients'
needs. Björn Hårdemark, Deputy CEO at RaySearch, will present a
preview of the system in the Accuray booth on Sunday, May 1, 2016 from 3:40 p.m. to 4:00 p.m.
- Multiple educational programs and opportunities
Accuray will host its satellite symposium titled, "Innovative
Patient Care: Present and Future," on Saturday, April 30, 2016 from 1:25 p.m. to 2:25 p.m. A panel of thought leaders
will discuss the latest innovations Accuray is bringing to the
radiotherapy market, and how frontier market countries have adopted
new technologies. In addition, Dr. Alexandra D. Jensen from Inselspital,
Bern will share how the
CyberKnife® System is being used to provide important improvements
in patient treatments while enhancing operational efficiency in the
radiation oncology department.
Accuray Exchange in Radiation Oncology (AERO™) Academy sessions
on an extensive range of topics will be held daily throughout the
meeting. Accuray hosts these educational events to provide
clinicians with the opportunity to engage in interactive
discussions on the real-world use of Accuray technologies. For more
information, please visit: http://www.accuray.com/estro35/.
*The Radixact™ Treatment Delivery System, Precision™
Treatment Planning System and iDMS™ Data Management System are
pending US FDA 510(k) clearance and not available for sale. These
products may also be subject to international regulatory approval
or licensing processes such that the availability of these products
may vary according to geographical location.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, anticipated regulatory
approvals and launches of new products, market uptake of recently
launched products, market adoption of the company's products and
Accuray's leadership position radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
under the heading "Risk Factors" in the company's report on Form
10-K, filed on August 28, 2015, the
company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.